News Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
2.1 ^USD	-1.41%		-15.32%	-29.77%

May. 22	Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	CI
May. 20	Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Esperion to Participate in Upcoming June Investor Conferences	May. 23	GL
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk	May. 22	GL
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk	May. 22	AQ
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	May. 22	CI
Esperion - Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia	May. 21	AQ
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise	May. 20	MT
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia	May. 20	GL
Transcript : Esperion Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	May. 14	GL
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®	May. 14	AQ
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)	May. 13	AQ
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	May. 10	GL
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS	May. 08	AQ
Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell	May. 07	MT
Top Premarket Gainers	May. 07	MT
Transcript : Esperion Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Esperion Therapeutics: Q1 Earnings Snapshot	May. 07	AQ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M	May. 07	MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01	May. 07	MT
Esperion Reports First Quarter 2024 Financial Results	May. 07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Summary

Filters